Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent obtained before any trial-related activities.~* Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months.~* Treated with insulin ≥ 12 months.~* Using a multiple dosing insulin therapy (MDI) with basal and bolus insulin.~* HbA1c ≤ 9.0%.~* Fasting negative C-peptide (≤ 0.30 nmol/L).~* Total daily prandial dose: ≤ 40U in the Part A and ≥ 40 U in the Part B~Exclusion Criteria:~* Known or suspected hypersensitivity to products used in the clinical trial~* Type 2 diabetes mellitus~* Previous participation in this trial. Participation is defined as randomized.~* Receipt of any medicinal product in clinical development within 3 months before randomization in this trial.~* Known slowing of gastric emptying, including gastroparesis, and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption.~* Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the Investigator.~* Intake of medication known to affect gastrointestinal motility, including but not limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol within 4 weeks before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Co-formulation of insulin analog and pramlintide (ADO09) (Type: EXPERIMENTAL): Subcutaneous injection of ADO09 formulation
- NovoRapid® (Type: ACTIVE_COMPARATOR): Subcutaneous injection of insulin aspart

Based on this trial design, predict the completion outcome and termination type (if applicable).